In adults, depending on grade and tumor subtype (e.g., oligodendroglioma vs. astrocytoma, IDH1-mutant vs. IDH1-wild-type) survival can range from a months to over a decade (Scorsetti et al., 2015; Society, 2017). Here, IDH1 is linked to astrocytoma (excluding glioblastoma).